Women In Bio Announces Expansion of Executive Women In Bio Program
DALLAS, March 25, 2025 /PRNewswire/ -- Women In Bio (WIB) celebrates an expansion of its Executive Women In Bio program that supports access to networking, community and collaboration for the thousands of women in biotech and life sciences.
New and existing partners of WIB have enabled the expansion of programming for the Executive Women In Bio program, the life science community's pre-eminent resource for executive women. EWIB champions for greater diversity in the industry and is committed to empowering women leaders at the highest levels by hosting robust professional development programs, creating targeted networking events, and fostering exclusive communities that amplify and support each other.
Starting this year, the program will bring WIB chapters together to provide collaborative and engaging programming to more executive women by increasing the number of virtual panels, roundtables, and networking opportunities, and developing unique in-person opportunities to connect.
'We're so pleased that our partners value our growing community and the impact our women leaders can make in biotech and life sciences,' said Gina Ford, executive director of Women In Bio. 'We are grateful for their trust and partnership in fueling our impactful programs and initiatives.'
Executive members of Women In Bio also have access to: Some additional programming for EWIB includes:
The Boardroom Ready Program, an award-winning exclusive executive development platform designed to fuel women's participation on corporate boards. Through a series of courses and applied learning sessions, participants are equipped with the knowledge they'll need to successfully seek board appointments. The 2025 application process is open and applications are due on April 21, 2025.
Executive Mentoring (eMAPS) programs offer cohort-based professional development for rising Directors, VPs, and C-Level executives.
Annual invite-only Luminary event during the JPM Healthcare Conference in San Francisco with life science's best leaders and influences
Renowned BIO International Convention panel and networking event — a must-attend event for C-Level executives, board members and aspiring board directors
Exclusive webinars featuring timely no-holds-bar conversations with industry icons
Local events in chapters across North America aimed at providing intimate conversation and connections
A new and exclusive LinkedIn Group for executive-level WIB members to connect, share, and learn.
About Women In Bio:
Women In Bio is a dynamic community that empowers women across the life sciences. With nearly 4,000 members and greater than 12,000 individuals engaging programming across 13 chapters in North America, we foster a vibrant community that connects professionals from diverse backgrounds – from biotech to academia. WIB supports women at every stage of their career, from students to board members. Through mentorship, networking and innovative programming, WIB provides touchpoints locally, regionally and nationally to foster innovative thinking across industries and functions, encouraging collaboration. By joining WIB, women can be part of a powerful community advancing women in the life sciences.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 hours ago
- Yahoo
New Mexico Delegation to Promote the State's Bioscience Industry at BIO International Convention in Boston
Delegates from public, private, and higher education entities will participate in the New Mexico Pavilion to create new connections and drive interest in the state's bioscience industry Albuquerque, NM, June 11, 2025 (GLOBE NEWSWIRE) -- A delegation of government, economic development, association and industry leaders and businesses will represent the New Mexico bioscience industry at the BIO International Convention in Boston June 16-19. The Albuquerque Regional Economic Alliance (AREA) will promote the New Mexico bioscience industry, learn about the latest bioscience trends, and connect with companies interested in relocating or expanding their business in greater Albuquerque. 'The greater Albuquerque region has a growing number of bioscience assets and workforce clusters that make it a prime location for medical technology companies,' said AREA President & CEO Danielle Casey. 'This conference gives us an opportunity to highlight assets driving that growth, to understand how to best support our local firms and to see how trends and technology are shaping site location and expansion decisions.' Representatives from AREA will exhibit at the conference with partners from Presbyterian Health, UNM Health Sciences, the New Mexico Bioscience Authority, Sandoval Economic Alliance, the New Mexico Economic Development Department, Tricore, Los Alamos National Labs. The City of Albuquerque, Bernalillo County and Sandoval County are also serving as sponsors of this effort. Each partner will highlight different aspects of the bioscience industry, which is broadly defined as any science that deals with the biological aspects of living organisms, by showcasing their respective organizations. 'Bernalillo County is ready and eager to partner with biotechnology businesses looking to expand in central New Mexico,' said Marcos Gonzales, Executive Development Officer for Bernalillo County. 'The I-40 TradePort Corridor is a key asset for companies seeking to integrate national or regional logistics and distribution capabilities into their growth strategies. If your expansion plans include logistics automation or multi-modal connectivity, we're here to find the right solution together.' 'The University of New Mexico Health Sciences Office of Research is honored to participate in the 2025 BIO International Convention,' said Dr. Hengameh Raissy, Vice President of Research at UNM Health Sciences. 'As part of the New Mexico booth, our team is eager to showcase groundbreaking research, build strategic partnerships, and explore new opportunities for collaboration that drive advancements in health and biomedical sciences. We are excited to engage with global leaders in biotechnology and life sciences, and to highlight the impactful work taking place at UNM Health Sciences and throughout New Mexico.' A featured and exciting showcase will occur on Tuesday, June 17 during the main exhibit hall reception, courtesy of Visit Albuquerque, where booth visitors will experience the thrill of a hot air balloon ride from the safety of the ground through virtual reality. The region has seen consistent growth within the industry, thanks to high concentrations of technical occupations, key regional assets like national laboratories and top-tier research universities, and a statewide talent pipeline of STEM-based graduates that has seen steady growth over the past five years. Overall, the state of New Mexico has seen a 26% job growth increase in the past five years in the bioscience cluster and 3,970 Statewide STEM Graduates. 'Albuquerque offers the innovation ecosystem, workforce, and infrastructure needed to help bioscience companies thrive and scale,' said Economic Development Director Max Gruner. 'We're committed to meeting businesses where they are and building new partnerships.' The BIO International Convention is the largest and most comprehensive event for biotechnology, representing the full ecosystem of biotech with over 20,000 industry leaders from across the globe. It is regarded as one of the most significant gatherings in the industry, providing a platform for New Mexico to connect and make strategic connections with investors, businesses interested in their research or products, and industry leaders from the pharmaceutical, med tech, life science, health care, government, and academic institutions. The Exhibition showcases over 500 exhibitors offering cutting-edge solutions in product development, contract research, contract manufacturing, and beyond, providing the New Mexico bioindustry an opportunity to build new partnerships and increase visibility and brand awareness of New Mexico as a leading location to do business. To view the New Mexico delegation's schedule of booth events and representatives, as well as reports and data on the bioscience industry in New Mexico, visit For more information about the conference, visit: About AREAThe Albuquerque Regional Economic Alliance is a 501(c)(3) nonprofit organization whose mission is to lead and execute strategies designed to grow and diversify the economic base of the greater Albuquerque region, creating a prosperous, diverse and inclusive economy and elevating the standard of living for all. AREA provides confidential assistance to businesses considering the area for expansion and new investment. Since its creation in 1960, AREA has recruited more than 250 companies and more than 35,000 jobs to the Albuquerque metro area. AREA also provides retention and expansion assistance to existing industry. For more information, visit CONTACT: Danielle Casey Albuquerque Regional Economic Alliance 505-705-3785 dcasey@
Business Wire
a day ago
- Business Wire
Niagen Bioscience to Participate in the BIO 2025 International Convention
LOS ANGELES--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced its participation in the 2025 BIO International Convention, taking place June 16–19, 2025, in Boston, Massachusetts. Niagen Bioscience to Participate in the BIO 2025 International Convention Share Hosted by the Biotechnology Innovation Organization (BIO), the BIO International Convention is the world's largest and most influential biotechnology event, convening more than 20,000 global leaders from across the life sciences ecosystem, including biopharma, academia, investment, and government. The convention provides companies with unique access to a partnering forum. By participating in BIO 2025, Niagen Bioscience is seeking to initiate discussions with prospective partners to support the development and monetization of its emerging drug product candidates. Niagen Bioscience is arranging a full slate of one-on-one meetings with pharmaceutical companies focused on neurodegenerative diseases, including Parkinson's disease (PD), Ataxia Telangiectasia (AT), among others, and plans to have partnering discussions. Attending from Niagen Bioscience's executive leadership team will be Ozan Pamir, CFO, Andrew Shao, Ph.D., Senior Vice President of Global Scientific and Regulatory Affairs, and Yasmeen Nkrumah-Elie, Ph.D., Senior Global Director of External Research. To request a meeting with the team, please reach out to the Company through the BIO Partnering platform at or email niagenir@ For additional information on Niagen Bioscience, visit About Niagen Bioscience: Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality. Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There's a better way to age. At the heart of its clinically proven product portfolio is Niagen® (patented nicotinamide riboside, or NR), the most efficient, well-researched, high-quality, and legal NAD+ booster available. Niagen powers the Company's consumer supplement, Tru Niagen®, the number one NAD+ boosting oral supplement in the United States† (available at and Niagen Plus™, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products ( Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. Niagen Bioscience's robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at where copies of press releases, news, and financial information are regularly published. †Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 1/1/2024 - 12/31/2024). Forward Looking Statements: This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to infringement or non-infringement of intellectual property rights. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include the preliminary status of the companies plans, strategies, and expectations concerning the pursuit of partnerships to develop and commercialize pharmaceutical candidates for the treatment of neurodegenerative diseases; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Niagen Bioscience undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
Yahoo
a day ago
- Yahoo
Niagen Bioscience to Participate in the BIO 2025 International Convention
LOS ANGELES, June 11, 2025--(BUSINESS WIRE)--Niagen Bioscience, Inc. (NASDAQ: NAGE) (formerly ChromaDex Corp.), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced its participation in the 2025 BIO International Convention, taking place June 16–19, 2025, in Boston, Massachusetts. Hosted by the Biotechnology Innovation Organization (BIO), the BIO International Convention is the world's largest and most influential biotechnology event, convening more than 20,000 global leaders from across the life sciences ecosystem, including biopharma, academia, investment, and government. The convention provides companies with unique access to a partnering forum. By participating in BIO 2025, Niagen Bioscience is seeking to initiate discussions with prospective partners to support the development and monetization of its emerging drug product candidates. Niagen Bioscience is arranging a full slate of one-on-one meetings with pharmaceutical companies focused on neurodegenerative diseases, including Parkinson's disease (PD), Ataxia Telangiectasia (AT), among others, and plans to have partnering discussions. Attending from Niagen Bioscience's executive leadership team will be Ozan Pamir, CFO, Andrew Shao, Ph.D., Senior Vice President of Global Scientific and Regulatory Affairs, and Yasmeen Nkrumah-Elie, Ph.D., Senior Global Director of External Research. To request a meeting with the team, please reach out to the Company through the BIO Partnering platform at or email niagenir@ For additional information on Niagen Bioscience, visit About Niagen Bioscience: Niagen Bioscience, Inc. (NASDAQ: NAGE), formerly ChromaDex Corp., is the global leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. As a trusted pioneer of NAD+ discoveries, Niagen Bioscience™ is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. The Niagen Bioscience team, composed of world-renowned scientists, works with independent investigators from esteemed universities and research institutions around the globe to uncover the full potential of NAD+. A vital coenzyme found in every cell of the human body, NAD+ declines with age and exposure to everyday lifestyle stressors. NAD+ depletion is a key contributor to age-related changes in health and vitality. Distinguished by state-of-the-art laboratories, rigorous scientific and quality protocols, and collaborations with leading research institutions worldwide, Niagen Bioscience sets the gold standard for research, quality, and innovation. There's a better way to age. At the heart of its clinically proven product portfolio is Niagen® (patented nicotinamide riboside, or NR), the most efficient, well-researched, high-quality, and legal NAD+ booster available. Niagen powers the Company's consumer supplement, Tru Niagen®, the number one NAD+ boosting oral supplement in the United States† (available at and Niagen Plus™, featuring pharmaceutical-grade intravenous (IV) and injectable Niagen products ( Pharmaceutical-grade Niagen IV and injections are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively at clinics with a prescription. Niagen Bioscience's robust patent portfolio protects NR and other NAD+ precursors. Niagen Bioscience maintains a website at where copies of press releases, news, and financial information are regularly published. †Based on the top-selling dietary supplement brands by revenue per the largest U.S. e-commerce marketplace (as of 1/1/2024 - 12/31/2024). Forward Looking Statements: This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to infringement or non-infringement of intellectual property rights. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. Risks that contribute to the uncertain nature of these forward-looking statements include the preliminary status of the companies plans, strategies, and expectations concerning the pursuit of partnerships to develop and commercialize pharmaceutical candidates for the treatment of neurodegenerative diseases; our history of operating losses and need to obtain additional financing; the growth and profitability of our product sales; our ability to maintain sales, marketing and distribution capabilities; changing consumer perceptions of our products; our reliance on a single or limited number of third-party suppliers; and the risks and uncertainties associated with our business and financial condition. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and Niagen Bioscience undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof. View source version on Contacts Niagen Bioscience Media Contact: Kendall Knysch, Senior Director of Media Relations & Niagen Bioscience Investor Relations Contact: ICR, LLCReed Anderson(646) 277-1260Stephanie Carrington(646) 277-1282niagenir@ Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
